University of Ottawa and The Ottawa Hospital Departments of Anesthesiology & Pain Medicine, Ottawa, Ontario, Canada.
Ottawa Hospital Research Institute, Ottawa, Ontario, Canada.
Ann Surg. 2019 Dec;270(6):1049-1057. doi: 10.1097/SLA.0000000000002765.
The aim of this study was to measure the association of preoperative anticholinergic exposure with length of stay (LOS) and other outcomes in older people having elective noncardiac surgery.
Anticholinergic medications are associated with adverse events in nonsurgical populations; the association of anticholinergic medications with outcomes in elective surgery patients is poorly described.
We conducted a retrospective, population-based cohort study using linked administrative data in Ontario, Canada. We identified all people >65 years old, from 2003 to 2014, having major, elective noncardiac surgery. Anticholinergic medication exposure was quantified using the Anticholinergic Risk Scale (ARS). Multilevel, multivariable modeling measured the adjusted association of ARS with LOS (primary outcome), institutional discharge, readmissions, costs, and survival (secondary outcomes).
Of 245,410 individuals, 71,569 had anticholinergic exposure (ARS 1-2, 15.6%; ARS ≥3, 13.6%). Median LOS was 5 days (interquartile range 3-7). Using proportional hazards analysis to model time to discharge, adjusting for in-hospital death as a competing risk, and surgical risk, demographic characteristics, and comorbidities, higher ARS scores were associated with longer LOS [smaller hazard ratios (HRs) mean longer LOS; ARS 1-2: adjusted HR 0.94, 95% confidence interval (CI), 0.93-0.95, P < 0.0001; ARS ≥3: adjusted HR 0.93, 95% CI, 0.91-0.95, P < 0.0001]. Similar associations were observed for all secondary outcomes.
Increasing ARS scores were associated with increased LOS, decreased survival, higher rates of institutional discharge and readmission, and higher costs of care. Perioperative interventional research to reduce the anticholinergic exposure in older surgical patients is likely warranted.
本研究旨在测量术前抗胆碱能药物暴露与老年人择期非心脏手术的住院时间(LOS)和其他结果的相关性。
抗胆碱能药物与非手术人群中的不良事件相关;抗胆碱能药物与择期手术患者结果的相关性描述较差。
我们使用加拿大安大略省的链接行政数据进行了回顾性、基于人群的队列研究。我们确定了所有 2003 年至 2014 年期间年龄大于 65 岁、接受主要择期非心脏手术的患者。使用抗胆碱能风险量表(ARS)量化抗胆碱能药物暴露。多水平、多变量模型测量了 ARS 与 LOS(主要结局)、机构出院、再入院、成本和生存(次要结局)的调整关联。
在 245410 名患者中,有 71569 名患者有抗胆碱能药物暴露(ARS 1-2,15.6%;ARS ≥3,13.6%)。中位 LOS 为 5 天(四分位距 3-7)。使用比例风险分析来模拟出院时间,将院内死亡作为竞争风险进行调整,并调整手术风险、人口统计学特征和合并症,较高的 ARS 评分与较长的 LOS 相关[较小的风险比(HR)意味着较长的 LOS;ARS 1-2:调整 HR 0.94,95%置信区间(CI)0.93-0.95,P <0.0001;ARS ≥3:调整 HR 0.93,95%CI,0.91-0.95,P <0.0001]。所有次要结局均观察到类似的关联。
ARS 评分的增加与 LOS 增加、生存率降低、机构出院和再入院率增加以及护理成本增加相关。可能需要对老年手术患者进行围手术期干预性研究以减少抗胆碱能药物的暴露。